Previous 10 | Next 10 |
NEW YORK , June 3, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Daniel L. Alkon , the Company's President and CSO, wi...
NEW YORK , May 30, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles Ryan , CEO, will be a featured presenter at t...
Immutep (NASDAQ: IMMP ) +50% on eftilagimod alpha in cancer patent in US. More news on: Immutep Limited, Bio-Path Holdings, Inc., Seelos Therapeutics, Inc., Stocks on the move, Read more ...
Gainers : SPI Energy (NASDAQ: SPI ) +69% . Sorrento Therapeutics (NASDAQ: SRNE ) +34% . Phunware (NASDAQ: PHUN ) +33% . Neurotrope (NASDAQ: NTRP ) +17% . Electrameccanica Vehicles (NASDAQ: SOLO ) +14% . General Finance (NASDAQ: GFN ) +14% . Axsome Therapeutics (NASDAQ: AXSM ) +13% ....
Buying has spiked in three biotechs developing treatments for Alzheimer's disease (AD) in apparent response to Biogen and Eisai's decision to bail on aducanumab . More news on: Neurotrope, Inc., Anavex Life Sciences Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks o...
NEW YORK , March 21, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its gl...
Neurotrope ( NTRP -3% ) has completed the enrollment of 108 subjects in its confirmatory Phase 2 clinical trial evaluating Bryostatin-1 in patients with moderate-to-severe Alzheimer's disease who are not on memantine. More news on: Neurotrope, Inc., Healthcare stocks news, Stocks on ...
NEW YORK , March 13, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has initiated dosing in the final patient in the...
Neurotrope (NASDAQ: NTRP ): FY GAAP EPS of -$1.37. Cash and cash equivalents of $28.85M. 10-K More news on: Neurotrope, Inc., Earnings news and commentary, Healthcare stocks news, ,
NEW YORK , March 11, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), provided financial results for the year ended December 31, 2018 . A...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Dynamic Content-to-Commerce FAST Channel Reinvents Monetization Models SUNRISE, FL / ACCESSWIRE / July 18, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, today announced that it has partnered with OTT ("over-the-top") services...
Allows Consumers to Pay for Accommodations Through Interest-free Installments with Convenient and Flexible Payment Options when Booking Travel Seamless Integration Enables Marketing Opportunities in Social Media Travel Package Campaigns and Direct-to-Consumer Marketing Channels to Drive Sale...